| Schedule of Stock Option Activity |
A summary of the Plans’ stock option activity for the three months ended March 31, 2026 and March 31, 2025 is presented below: | | | | | | | | | | | | | | | | | | | | | | | | | Stock Options | Common
Shares | | Weighted
Average
Strike Price | | Remaining Contractual Term (1) | | Intrinsic Value (2) (in thousands) | Outstanding at January 1, 2026 | 5,675 | | | $ | 44.81 | | | | | | | Granted | — | | | — | | | | | | | Exercised | (2,325) | | | 40.97 | | | | | | | Forfeited or canceled | — | | | — | | | | | | Outstanding at March 31, 2026 | 3,350 | | | $ | 47.47 | | | 2.8 | | $ | 306 | | Exercisable at March 31, 2026 | 3,350 | | | $ | 47.47 | | | 2.8 | | $ | 306 | |
| | | | | | | | | | | | | | | | | | | | | | | | | Stock Options | Common
Shares | | Weighted
Average
Strike Price | | Remaining Contractual Term (1) | | Intrinsic Value (2) (in thousands) | Outstanding at January 1, 2025 | 10,825 | | | $ | 43.76 | | | | | | | | | | | | | | | Granted | — | | | — | | | | | | | Exercised | (5,150) | | | 42.61 | | | | | | | Forfeited or canceled | — | | | — | | | | | | Outstanding at March 31, 2025 | 5,675 | | | $ | 44.81 | | | 3.4 | | $ | 384 | | Exercisable at March 31, 2025 | 5,675 | | | $ | 44.81 | | | 3.4 | | $ | 384 | |
(1)Represents the remaining weighted average contractual life in years. (2)Aggregate intrinsic value represents the total pre-tax intrinsic value (i.e., the difference between the Company’s stock price on the last trading day of the quarter and the option exercise price, multiplied by the number of shares) that would have been received by the option holders if they had exercised their options on the last day of the quarter. Options with exercise prices above the stock price on the last trading day of the quarter are excluded from the calculation of intrinsic value. The intrinsic value will change based on the fair market value of the Company’s stock.
|
| Schedule of Plans' Restricted and Performance Share Award Activity |
A summary of the Plans’ restricted share activity for the three months ended March 31, 2026 and March 31, 2025 is presented below: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended March 31, 2026 | | Three months ended March 31, 2025 | | Restricted Shares | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Outstanding at January 1 | 888,398 | | | $ | 101.63 | | | 880,866 | | | $ | 90.95 | | | Granted | 246,987 | | | 153.55 | | | 245,654 | | | 133.61 | | | Vested and issued | (268,760) | | | 93.29 | | | (192,866) | | | 94.94 | | | Forfeited or canceled | (7,356) | | | 117.07 | | | (7,587) | | | 103.76 | | Outstanding at March 31 | 859,269 | | | $ | 119.23 | | | 926,067 | | | $ | 101.33 | | Vested, but deferred, at March 31 | 102,584 | | | $ | 55.94 | | | 101,000 | | | $ | 54.75 | |
A summary of the Plans’ performance-based stock award activity, based on the target level of the awards, for the three months ended March 31, 2026 and March 31, 2025 is presented below: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended March 31, 2026 | | Three months ended March 31, 2025 | | Performance-based Stock | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Common
Shares | | Weighted
Average
Grant-Date
Fair Value | | Outstanding at January 1 | 377,757 | | | $ | 102.38 | | | 454,017 | | | $ | 93.57 | | | Granted | 85,822 | | | 148.36 | | | 86,524 | | | 134.69 | | | Added by performance factor at vesting, net | 9,242 | | | — | | | 75,461 | | | — | | | Vested and issued | (196,899) | | | 90.33 | | | (230,957) | | | 95.26 | | | Forfeited or canceled | (336) | | | 112.99 | | | (2,902) | | | 97.28 | | Outstanding at March 31 | 275,586 | | | $ | 125.92 | | | 382,143 | | | $ | 102.41 | | Vested, but deferred, at March 31 | — | | | $ | — | | | 13,176 | | | $ | 40.20 | |
|